|
Variable
|
EIF4A2
|
ANKRD46
|
|---|
| |
Low (n = 21)
|
High (n = 78)
|
P*
|
Low (n = 47)
|
High (n = 52)
|
P*
|
|---|
|
Age (years)
| | | | | | |
|
< 48
|
8
|
39
|
0.332
|
23
|
24
|
0.782
|
|
≥ 48
|
13
|
39
| |
24
|
28
| |
|
Pathologic grade
| | | | | | |
|
I
|
2
|
20
|
0.115
|
14
|
10
|
0.221
|
|
II, III
|
19
|
58
| |
33
|
42
| |
|
Clinical stage**
| | | | | | |
|
I, II
|
15
|
61
|
0.514
|
41
|
37
|
0.051
|
|
III
|
6
|
17
| |
6
|
15
| |
|
Lymph node status
| | | | | | |
|
Metastasis
|
14
|
43
|
0.342
|
23
|
34
|
0.098
|
|
No Metastasis
|
7
|
35
| |
24
|
18
| |
|
ER status
| | | | | | |
|
Negative
|
12
|
36
|
0.371
|
18
|
32
|
0.021
|
|
Positive
|
9
|
42
| |
29
|
20
| |
|
PR status
| | | | | | |
|
Negative
|
11
|
28
|
0.170
|
11
|
29
|
0.001
|
|
Positive
|
10
|
50
| |
36
|
23
| |
|
CerbB2 status
| | | | | | |
|
0,1+
|
17
|
41
|
0.019
|
29
|
18
|
0.832
|
|
2+,3+
|
4
|
37
| |
31
|
21
| |
- *Two-sided Pearson Chi-Square Test; ** there were no stage IV patients because all the cases selected were surgical patients without neoadjuvant therapy to avoid the effect of the preoperative radiotherapy and/or chemotherapy on miRNAs; EIF4A2, eukaryotic translation initiation factor 4A2 protein; ANKRD46, ankyrin repeat domain 46 protein; ER, estrogen receptor; PR, progesterone receptor; CerbB2, v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2 receptors.
